Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
9-valent recombinant human papillomavirus vaccine
- Development stage
- Unknown
- Lead developer
- Ab&B Bio-tech Co., Ltd.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A 9-valent recombinant human papillomavirus (HPV) vaccine developed by Jiangsu Zhonghui Yuantong Biotechnology. The vaccine is produced using a *Pichia pastoris* yeast expression system and is composed of purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is designed to elicit a humoral immune response, producing neutralizing antibodies that prevent HPV infection and subsequent development of cervical, vulvar, vaginal, and anal cancers, as well as genital warts. The candidate is currently in Phase I/II clinical trials in China to evaluate its safety, immunogenicity, and various immunization schedules in healthy women.
- Other names
- 9-valent recombinant human papillomavirus vaccine (Pichia pastoris)9vHPV vaccine
02
Targets
HPV18 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)Human papillomavirus type 31 L1 capsid proteinHPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)L1 (Major capsid protein L1 (Human papillomavirus 33))HPV16 (Human papillomavirus type 16)Human papillomavirus type 45 L1 capsid protein (HPV45 L1)HPV11 L1
Beyond the preview
Go deeper on 9-valent recombinant human papillomavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 9-valent recombinant human papillomavirus vaccine.